Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication

Review Series 10.1172/JCI129188

β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes

Laura I. Hudish,1 Jane E.B. Reusch,2 and Lori Sussel1

1Barbara Davis Center and

2Division of Endocrinology, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.

Address correspondence to: Lori Sussel, University of Colorado Anschutz Medical Center, 1775 Aurora Ct., Aurora, Colorado 80045, USA. Phone: 303.724.9119. Email: lori.sussel@cuanschutz.edu.

Find articles by Hudish, L. in: JCI | PubMed | Google Scholar

1Barbara Davis Center and

2Division of Endocrinology, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.

Address correspondence to: Lori Sussel, University of Colorado Anschutz Medical Center, 1775 Aurora Ct., Aurora, Colorado 80045, USA. Phone: 303.724.9119. Email: lori.sussel@cuanschutz.edu.

Find articles by Reusch, J. in: JCI | PubMed | Google Scholar

1Barbara Davis Center and

2Division of Endocrinology, University of Colorado Anschutz Medical Center, Aurora, Colorado, USA.

Address correspondence to: Lori Sussel, University of Colorado Anschutz Medical Center, 1775 Aurora Ct., Aurora, Colorado 80045, USA. Phone: 303.724.9119. Email: lori.sussel@cuanschutz.edu.

Find articles by Sussel, L. in: JCI | PubMed | Google Scholar |

First published August 19, 2019 - More info

Published in Volume 129, Issue 10 on October 1, 2019
J Clin Invest. 2019;129(10):4001–4008. https://doi.org/10.1172/JCI129188.
© 2019 American Society for Clinical Investigation
First published August 19, 2019 - Version history

In a society where physical activity is limited and food supply is abundant, metabolic diseases are becoming a serious epidemic. Metabolic syndrome (MetS) represents a cluster of metabolically related symptoms such as obesity, hypertension, dyslipidemia, and carbohydrate intolerance, and significantly increases type 2 diabetes mellitus risk. Insulin resistance and hyperinsulinemia are consistent characteristics of MetS, but which of these features is the initiating insult is still widely debated. Regardless, both of these conditions trigger adverse responses from the pancreatic β cell, which is responsible for producing, storing, and releasing insulin to maintain glucose homeostasis. The observation that the degree of β cell dysfunction correlates with the severity of MetS highlights the need to better understand β cell dysfunction in the development of MetS. This Review focuses on the current understanding from rodent and human studies of the progression of β cell responses during the development of MetS, as well as recent findings addressing the complexity of β cell identity and heterogeneity within the islet during disease progression. The differential responses observed in β cells together with the heterogeneity in disease phenotypes within the patient population emphasize the need to better understand the mechanisms behind β cell adaptation, identity, and dysfunction in MetS.

Preview pages

Reset
Page preview
4002 Page 4001 Back

Continue reading with a subscription.

A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.

Already subscribed?

Click here to sign into your account.

Don't have a subscription?

Please select one of the subscription options, which includes a low-cost option just for this article.

At an institution or library?

If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).

Problems?

Please try these troubleshooting tips.

  • Purchase this article
  • $10
  • Purchasing this article will give you full access for the calendar year.
  • Purchase article
  • Purchase Site Pass
  • $25
  • This will give you access to every article on the site for 24 hours.
  • Order site pass
  • Online subscription
  • $95
  • Individual online subscriptions give you full online access for the calendar year.
  • Individual online subscriptions ordered from September 1st on will receive access for the remainder of current year as well as for the full following year subscription term.
  • Order Online
  • Print subscription
  • $830
  • Individual print subscriptions give you the print journal and full online access for the year.
  • Print + Online
  • JCI This Month subscription
  • $125
  • JCI This Month is a 16- to 20-page overview of the articles published each month
  • Subscribing to JCI This Month also gives subscribers full online access for the calendar year.
  • *Price outside U.S. and Canada: $225.
  • JCI This Month + Online
Advertisement
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts